EX-23.2 17 avte-20240930xex23d2.htm EXHIBIT 23.2

Exhibit 23.2

​

Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated March 25, 2024, with respect to the consolidated financial statements of Aerovate Therapeutics, Inc., included herein, and to the reference to our firm under the heading "Experts" in the prospectus.

/s/ KPMG LLP

San Diego, California
December 2, 2024

​